AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of the claims:

- 1. (currently amended) A method for screening eompounds a compound useful for the treatment of proliferative and differentiative disorders comprising contacting a test compound in vitro with a cell or a cell extract expressing Cks1 and Skp2 a reaction mixture comprising Skp2, p27, Cdk2 and Cks1; and detecting a change in Skp2 binding activity or Skp2 ubiquitin ligase activity, such that if a change in the binding activity or ubiquitin ligase activity of Skp2 is detected, then a compound useful for the treatment of proliferative or differentiative disorders is identified.
- 2. (previously presented) The method of claim 1 wherein the change in Skp2-binding activity is detected by detecting a change in the binding of Skp2 with either p27 or Cks1.
- 3. (currently amended) The method of Claim 1 wherein the change in the-Skp2 ubiquitin ligase activity is detected by detecting a change in the ubiquitination or degradation of a Skp2 specific substrate p27 or Cks1.
- 4. (canceled)
- 5. (canceled)
- 6. (canceled)
- 7. (currently amended) A method for screening <u>a compound</u> eompounds useful for the treatment of proliferative and differentiative disorders comprising:
 - (a) contacting adding a test compound to a with a reaction mixture containing Skp2,

 Cks1, and a and one or both of: (i) a polypeptide corresponding to comprising the carboxy terminus of the human p27 chain having the sequence

 NAGSVEWTPKKPGLRRRQT (SEQ. ID. NO: 91) with or without a phosphothreonine at position 8 and (ii) Cks1; and

- (b) detecting a change in the interaction of Skp2 with Cks1 or the polypeptide, such that if a change in the interaction of Skp2 with Cks1 or the polypeptide is detected, then a compound useful for the treatment of proliferative and differentiative disorders is identified.
- 8. (previously presented) The method of Claim 7 wherein the change in the interaction of Skp2 with Cks1 or the polypeptide is detected by detecting a change in the binding of Skp2 to either the polypeptide or Cks1.
- 9. (previously presented) The method of Claim 7 wherein the change in the interaction of Skp2 with Cks1 or the polypeptide is detected by detecting a change in the ubiquitination or degradation of the polypeptide.



- 20. (canceled)
- 21. (canceled)
- 22. (new) The method of claim 1 or 7 wherein said Cks1 is purified from an *in vitro* translation reaction or recombinant expression system.
- 23. (new) The method of claim 2 or 8 wherein the change in binding of Skp2 to Cks1 is detected by detecting an increase in the binding of Skp2 to Cks1.
- 24. (new) The method of claim 2 or 8 wherein the change in binding of Skp2 to Cks1 is detected by detecting a decrease in the binding of Skp2 to Cks1.
- 25. (new) The method of claim 2 wherein the change in binding of Skp2 and p27 is detected by detecting an increase in the binding of Skp2 to p27.
- 26. (new) The method of claim 2 wherein the change in binding of Skp2 and p27 is detected by detecting a decrease in the binding of Skp2 to p27.